Donate
info@cureduchenne.org(949) 872-2552
EventsContact
Cart
×

No products in the cart.

CureDuchenne
Moble Nav Icon
  • Cure
    • Research Overview
    • Research Terms
    • Exon Skipping
    • Clinical Trials
  • Care
    • COVID-19 Resources
    • Newly Diagnosed
    • Clinics
    • Steroid Use
    • Emergency Care
    • Resource Library
    • DME Guide
    • Medical ID Bracelets
    • Navigating School
    • Occupational Therapy
    • Physical Therapy
    • For Families
    • - Find a Physical Therapist
    • - Pool Activities
    • - Stretching
    • For Physical Therapists
    • - PT Certification
    • - Professional Courses
    • For Clinics
  • Community
    • CureDuchenne CARES
    • CureDuchenne FUTURES
    • CureDuchenne Champions
    • Family Stories
    • Events
    • Previous Webinars
    • Family Fundraisers
  • About Us
    • Mission
    • Vision
    • About Duchenne
    • Blog
    • Board of Directors
    • Sponsors
    • Reports and Financials
    • Events & Webinars
    • News Center
    • - Press Releases
    • - Research
  • CD Ventures
    • About CD Ventures
    • Our Impact
  • Get Involved
    • Donate
    • More Ways to Give
    • Fundraise
    • Shop
    • Fundraising Events
    • - Ladies Luncheon Austin
    • - CureDuchenne Golf Shootout | Orange County, CA
    • - Napa in Newport | Orange County, CA
  • Donate
  • All
  • Cure Duchenne Blog
  • Press Releases
  • CureDuchenne In The News
  • Research
Duchenne cardiomyopathy

Capricor completes BLA submission to the FDA for the approval of its investigational cell therapy for Duchenne cardiomyopathy

January 2, 2025

Capricor Therapeutics, which received early funding from CureDuchenne, has completed a Biologics License Application (BLA) with the US FDA, seeking full approval of deramiocel for individuals with Duchenne cardiomyopathy.  Deramiocel […]

Read More
Exon 51

PepGen’s DMD Exon 51 Skipping Program On Clinical Hold In US

December 16, 2024

PepGen has received a clinical hold notice from the FDA regarding its Investigational New Drug (IND) application in Duchenne amenable to skipping exon 51, and will be unable to initiate […]

Read More
Honoring Mats Steen

Honoring Mats Steen: How a World of Warcraft Hero is Helping CureDuchenne Find a Cure for Duchenne Muscular Dystrophy 

November 5, 2024

By Debra Miller, Founder and CEO of CureDuchenne  I’m honored to share two transformative events that embody both the resilience of the human spirit and the strength of our community: […]

Read More
PTC FDA Duchenne Nonsense mutation

FDA will review resubmission of PTC’s Translarna for Duchenne caused by nonsense mutation

October 30, 2024

CureDuchenne is pleased to share that PTC Therapeutics has announced that the FDA has accepted for review the New Drug Application (NDA) for Translarna (ataluren) for the treatment of Duchenne […]

Read More
World of Warcraft

The Remarkable Life of Ibelin: A Life Rich with Community and Connection through World of Warcraft

October 24, 2024

Read a message from our founder and CEO The recently released award-winning Netflix documentary “The Remarkable Life of Ibelin,”* highlights the life of Mats Steen, a Norwegian World of Warcraft […]

Read More
2024 world muscle

2024 Annual Congress of the World Muscle Society Updates

October 9, 2024

CureDuchenne Shares Updates from 29th Annual Congress of the World Muscle Society  We’re at the 29th Annual Congress of the World Muscle Society this week and are pleased to share […]

Read More
Wave Life Sciences Exon Skipping

Positive Interim Data from Wave Life Sciences Exon 53 Skipping Program

September 24, 2024

CureDuchenne is pleased to communicate that Wave Life Sciences announced positive interim data from the ongoing Phase 2 FORWARD-53 study in Duchenne amenable skipping exon 53.  After 24 weeks of […]

Read More
Dyne Duchenne Data

Dyne Therapeutics Announces New Clinical Data from Phase 1/2 DELIVER Trial of DYNE-251 in Duchenne Muscular Dystrophy Demonstrating Unprecedented Dystrophin Expression and Functional Improvement in Multiple Cohorts

September 3, 2024

As an early investor in Dyne Therapeutics, CureDuchenne is pleased share that Dyne announced positive data from their Phase 1/2 trial of DYNE-251 in individuals with Duchenne amenable to skipping […]

Read More
Ryan Getzlaf

Global Nonprofit CureDuchenne to Host Informational Webinars Following FDA Label Expansion of Sarepta Therapeutics’ Gene Therapy, ELEVIDYS

June 21, 2024

NEWPORT BEACH, Calif., June 20, 2024 /PRNewswire/ — CureDuchenne, a global nonprofit committed to finding and funding a cure for Duchenne muscular dystrophy, will host webinars in English and Spanish for the Duchenne community […]

Read More
  • « Previous Page
  • 1
  • …
  • 5
  • 6
  • 7
  • 8
  • Next Page »
  • About

    • Mission
    • About Duchenne MD
    • Blog
    • Store
    • News Center
  • Get Involved

    • Donate
    • Fundraising
    • Attend an Event
  • CureDuchenne

    • 100 Bayview Circle, Suite 5600
      Newport Beach, CA 92660
      (949) 872-2552
      info@cureduchenne.org

  • Get Connected

  • Charity Navigator Four-Star Charity
  • Candid Platinum Transparency Seal

PRIVACY POLICY | TERMS OF USE | INDIRECT COST POLICY | TAX INFO

CureDuchenne is a 501c3 registered tax-exempt nonprofit organization. Federal Tax ID: #20-0299958 | ©2026 CureDuchenne. All rights reserved.

Please be advised that the contents within the CureDuchenne site include a compilation of articles, advisements, and references from the community. CureDuchenne does not provide medical advice nor is CureDuchenne a medical provider. The intent of this shared content is to serve as a point of reference for informational purposes. Please refer to your health care provider(s) for your individualized, specific care management needs. The CureDuchenne website may contain links to external websites that are not provided and/or maintained by or in any way affiliated with CureDuchenne. CureDuchenne recommends that you review the terms of service and privacy policies of these external websites before entering. Please note that CureDuchenne does not guarantee the accuracy, relevance, timeliness, or completeness of any information on these external websites.

We use cookies to ensure that we give you the best experience on our website. By continuing to use this site you are agreeing to accept our use of cookies. For more information about cookies please visit our Privacy Policy page.